CSL Seqirus published pivotal Phase 3 study results for its AUJEMFLU® quadrivalent influenza vaccine in The Lancet Infectious Diseases. The peer-reviewed data validates the first vaccine to combine an adjuvant (MF59®), cell-based manufacturing, and a higher dose.
This triple-technology approach aims to enhance protection for adults aged 50 and older. The European Commission and the United Kingdom recently approved AUJEMFLU® for this demographic.
This large-scale study provides the first comprehensive evaluation of these combined technologies. Each individual technology within the vaccine already possesses a proven track record. CSL describes the publication as a significant advance in influenza prevention following decades of investment.